European regulator approves two treatments for the crown

Ronapreve (casirivimab/imdevimab) is indicated for the treatment of COVID-19 in adults and children over 12 years of age who do not require supplemental oxygen but are at risk of serious illness. Treatment can also have a preventive effect. Ronapreve is given intravenously, by infusion or injection.

The treatment has already been approved under an emergency procedure in several other countries, including the United Kingdom and the United States. Former US President Donald Trump received treatment last year after contracting the Corona virus, when the antibody mixture had not yet been officially approved in the United States.

Regkirona (regdanvimab) is only recommended by the EMA for adults who do not need supplemental oxygen but are at risk of serious illness.

They are the first treatments to use the recommended Covid-19 antibody cocktails for EMA approval. The European Commission has not yet confirmed the approval.

So far, only Veklury (remdesivir) has been approved as a special drug for coronavirus in the European Union. It was developed by the American company Gilead Sciences.

See also  Pnrr: Treu (Cnel), the science of little interest - workers and companies

Leave a Reply

Your email address will not be published. Required fields are marked *